SecBot SecBot
SECBOTREPLAY Home › Report › ONCY

ONCY · Pelareorep MM data at ASH

Oncolytics Biotech, Inc. · PRESS-RELEASE filed Nov 9, 2026 at 09:30 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Nov 9, 2026 at 09:30 ET

Oncolytics Biotech announced translational data from a Phase 1b/2 trial of pelareorep in heavily pretreated relapsed/refractory multiple myeloma, to be presented at the ASH annual meeting. The data show immune activation and direct tumor effects, but this is an early-stage, non-regulatory update with no new clinical endpoints or financial guidance.

  • Translational data from Phase 1b/2 trial in relapsed/refractory multiple myeloma patients with median 4 prior lines of therapy
  • Data show enhanced antigen-presenting activity, increased apoptotic signaling, and expansion of CD8 effector memory T cells
  • Clinical responders had greater CD8 EM T cell expansion and lower T cell exhaustion vs non-responders
  • Data to be presented at ASH annual meeting on December 12, 2026 (abstract #2183)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access